Agios Pharmaceuticals (AGIO) Enterprise Value (2016 - 2025)
Historic Enterprise Value for Agios Pharmaceuticals (AGIO) over the last 14 years, with Q3 2025 value amounting to -$952.9 million.
- Agios Pharmaceuticals' Enterprise Value rose 516.51% to -$952.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$952.9 million, marking a year-over-year increase of 516.51%. This contributed to the annual value of -$893.7 million for FY2024, which is 1503.13% down from last year.
- Per Agios Pharmaceuticals' latest filing, its Enterprise Value stood at -$952.9 million for Q3 2025, which was up 516.51% from -$938.9 million recorded in Q2 2025.
- Agios Pharmaceuticals' 5-year Enterprise Value high stood at -$569.9 million for Q2 2024, and its period low was -$2.3 billion during Q1 2021.
- Over the past 5 years, Agios Pharmaceuticals' median Enterprise Value value was -$893.4 million (recorded in 2025), while the average stood at -$961.4 million.
- In the last 5 years, Agios Pharmaceuticals' Enterprise Value tumbled by 34182.94% in 2021 and then skyrocketed by 6045.86% in 2022.
- Over the past 5 years, Agios Pharmaceuticals' Enterprise Value (Quarter) stood at -$1.0 billion in 2021, then rose by 23.22% to -$783.1 million in 2022, then increased by 0.79% to -$776.9 million in 2023, then decreased by 15.03% to -$893.7 million in 2024, then decreased by 6.62% to -$952.9 million in 2025.
- Its Enterprise Value was -$952.9 million in Q3 2025, compared to -$938.9 million in Q2 2025 and -$893.4 million in Q1 2025.